TRACON Pharmaceuticals, Inc. (TCON)

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
kilimanjaro
Forum newbie
Forum newbie
Berichten: 10
Lid geworden op: 11 Sep 2015 14:30
waarderingen: 1
Contact:

TRACON Pharmaceuticals, Inc. (TCON)

Berichtdoor kilimanjaro » 11 Sep 2015 14:36

huidige koers 11.99$
Day's Range: 10.45 - 12.11

Bedrijf staat sinds een half jaar op de beurs. Pareltje voor de komende weken, maanden. Lage float; laag volume, onder de radar van velen,

TrACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration (“AMD”) and fibrotic diseases. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In March 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our anti-endoglin antibodies for ophthalmology indications, including AMD. We retain global rights to develop and commercialize our anti-endoglin antibodies outside of the field of ophthalmology, as well as global rights to TRC102 in all indications.

Pipeline

http://www.traconpharma.com/programs.php" onclick="window.open(this.href);return false;

[img]http://www.traconpharma.com/images/pipeline.jpg[/img]

Statistics

Avg Vol (3 month)3: 54,064
Avg Vol (10 day)3: 43,986
Shares Outstanding5: 12.10M
Float: 7.35M
% Held by Insiders1: N/A
% Held by Institutions1: N/A
Shares Short (as of Aug 14, 2015)3: 152.63K
Short Ratio (as of Aug 14, 2015)3: 2.11
Short % of Float (as of Aug 14, 2015)3: 2.48%
Shares Short (prior month)3: 166.16K

Income Statement
Revenue (ttm): 7.50M
Revenue Per Share (ttm): 1.28
Qtrly Revenue Growth (yoy): 292.60%
Gross Profit (ttm): 3.60M
EBITDA (ttm)6: -10.32M
Net Income Avl to Common (ttm): -11.58M
Diluted EPS (ttm): -1.98
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 61.16M
Total Cash Per Share (mrq): 5.05
Total Deb t (mrq): 6.81M
Total Deb t/Equity (mrq): 14.56
Current Ratio (mrq): 6.02
Book Value Per Share (mrq): 0.00
Cash Flow Statement
Operating Cash Flow (ttm): -12.82M
Levered Free Cash Flow (ttm): -5.45M


The Small-Cap Biotech That Could Double After New Data Is Released Mid-September

Shares of TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) have risen 16.91 percent, year to date.
Ling Wang of Oppenheimer has maintained an Outperform rating and price target of $26 on the company.
The company is expected to announce single-patient data for its Phase II compassionate-use study at the World Congress on Gestational Trophoblastic Neoplasia on September 15-18, 2015.
According to the Oppenheimer report, “The data will be derived from a single patient with refractory and metastatic choriocarcinoma who was treated with TRC105+Avastin.”

Wang believes that choriocarcinoma is the ideal disease model to test the drug and mentioned that if positive activity was demonstrated, there would be potential for “further clinical development in this ultra-orphan indication.”

There are an estimated 200 new cases of choriocarcinoma every year in the US. At present, there are very few second-line treatment options for patients who fail front-line treatment. “TRC105, a potent and highly selective endoglin inhibitor, has the potential to be a second-line choice for choriocarcinoma patients, nearly all of whom overexpress endoglin,” Wang stated.

Apart from the Phase II data for TRC105, other upcoming catalysts for the stock include updated data on Phase II sarcoma study for TRC105+Votrient, expected in early 2016, and updated data for Phase II RCC for TRC105+Inlyta, expected in mid-2016.

http://finance.yahoo.com/news/small-cap ... 21214.html" onclick="window.open(this.href);return false;

5/15/2015 7:12:30

SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TRC105 in patients with advanced renal cell carcinoma (RCC) that have progressed following treatment with one inhibitor of the VEGF pathway in combination with standard dose Inlyta® (axitinib).

The FDA created the Fast Track designation process to facilitate the development and expedite the review of drugs to treat serious diseases and address unmet medical needs. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met.

TRACON is sponsoring a multicenter, open-label, randomized clinical trial of TRC105 in combination with AXitinib in patients with Advanced or metastatic RCC (TRAXAR). The primary endpoint of the Phase 2b study is progression-free survival. Approximately 150 patients with clear cell RCC who have failed one prior VEGF inhibitor are expected to enroll in the study. Patients may have also failed one prior mTOR inhibitor and one prior immunotherapy. For additional information on this clinical trial, please visit clinicaltrials, identifier NCT01806064.
piddybull liked last!



kilimanjaro
Forum newbie
Forum newbie
Berichten: 10
Lid geworden op: 11 Sep 2015 14:30
waarderingen: 1
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON) -NasdaqGM 11.99$

Berichtdoor kilimanjaro » 18 Sep 2015 13:57

TRACON Pharmaceuticals Reports Ongoing Complete Response in Choriocarcinoma Patient Treated With Company's TRC105 in Compassionate Use Phase 2 Clinical Trial Conducted at Dana-Farber Cancer Institute

he single patient compassionate use Phase 2 clinical trial enrolled a 37-year old woman with persistent and unresectable metastatic choriocarcinoma, an aggressive form of gestational trophoblastic neoplasia (GTN). Prior to entry into the trial, the patient had received multiple treatments, including laparoscopic hysterectomy, five prior chemotherapy regimens and stem cell transplant.

The patient was treated with TRC105 dosed 10 mg/kg weekly in combination with Avastin® (bevacizumab) dosed 10 mg/kg every other week. As of the time of the presentation, the patient had completed 7 cycles (28 weeks) of treatment. Beta human chorionic gonadotropin (β-hCG), a known, reliable marker of disease burden in choriocarcinoma, normalized during the fourth cycle of treatment, decreasing from greater than 3,000 IU/L at treatment initiation to less than 1 IU/L from cycles 4 through 7, indicating an ongoing complete response.

Choriocarcinoma represents the second tumor type known to express high levels of endoglin in which complete durable responses have been observed following treatment with a combination of TRC105 and a VEGF inhibitor. In June 2015, Dr. Steven Attia of the Mayo Clinic reported complete responses in two patients with angiosarcoma, treated with TRC105 and Votrient® (pazopanib), at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

"We have now seen complete responses in two orphan tumor types that overexpress endoglin, choriocarcinoma and angiosarcoma. There are currently limited treatment options for patients with either of these cancers who progress on first-line chemotherapy," said Charles P. Theuer, M.D., Ph.D., President and CEO of TRACON. "We intend to treat additional patients with GTN in a Phase 2 multicenter trial that we expect to initiate in the fourth quarter of 2015, and to apply for orphan drug status for TRC105 in GTN, as well as soft tissue sarcoma, by the end of the year."
https://www.morningstar.com/news/globe- ... itute.html" onclick="window.open(this.href);return false;

kilimanjaro
Forum newbie
Forum newbie
Berichten: 10
Lid geworden op: 11 Sep 2015 14:30
waarderingen: 1
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON) -NasdaqGM 11.99$

Berichtdoor kilimanjaro » 18 Sep 2015 14:08

premarket up 15$

Pre-Market Volume: Pre-Market High: Pre-Market Low:
1,940 $ 18.25 $ 13.48

kilimanjaro
Forum newbie
Forum newbie
Berichten: 10
Lid geworden op: 11 Sep 2015 14:30
waarderingen: 1
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON) -NasdaqGM 11.99$

Berichtdoor kilimanjaro » 18 Sep 2015 14:21

pre market raket

Follow
TRACON Pharmaceuticals, Inc. (TCON) Pre-Market Trading
TCON
$24.37
*
12.64
107.76%
Get TCON Alerts

Gebruikersavatar
Jojo
Premiummember
Premiummember
Berichten: 498
Lid geworden op: 19 Dec 2013 15:26
waarderingen: 151
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON) -NasdaqGM 11.99$

Berichtdoor Jojo » 14 Jun 2017 08:56

iemand die dit aandeel nog volgt ?
Gilead Ageas Genmab ASMI Sphere3D GSK CFEB LBrands Melexis Umicore Euronav Nordex Solvay Grandvision Biocartis AXA Befimmo AHDelh ABInbev TCON ACIU BMW RioTinto

Gebruikersavatar
Pantanirulez
Forum gebruiker
Forum gebruiker
Berichten: 147
Lid geworden op: 17 Aug 2015 15:32
waarderingen: 55
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON) -NasdaqGM 11.99$

Berichtdoor Pantanirulez » 27 Jun 2017 20:12

https://huronreport.com/sasco-capital-has-raised-sealed-air-see-stake-tracon-pharmaceuticals-tcon-sellers-increased-by-3-55-their-shorts
Sasco Capital Has Raised Sealed Air (SEE) Stake; Tracon Pharmaceuticals (TCON) Sellers Increased By 3.55% Their Shorts
June 27, 2017 -By wolcottdaily


Sasco Capital Inc increased Sealed Air Corp (SEE) stake by 52.69% reported in 2016Q4 SEC filing. Sasco Capital Inc acquired 868,140 shares as Sealed Air Corp (SEE)’s stock declined 9.02%. The Sasco Capital Inc holds 2.52M shares with $114.07 million value, up from 1.65M last quarter. Sealed Air Corp now has $8.95B valuation. The stock declined 0.31% or $0.14 reaching $45.2 on the news. About 530,128 shares traded. Sealed Air Corp (NYSE:SEE) has declined 6.94% since June 27, 2016 and is downtrending. It has underperformed by 23.64% the S&P500.

Tracon Pharmaceuticals Incorporated (NASDAQ:TCON) had an increase of 3.55% in short interest. TCON’s SI was 365,000 shares in June as released by FINRA. Its up 3.55% from 352,500 shares previously. With 26,400 avg volume, 14 days are for Tracon Pharmaceuticals Incorporated (NASDAQ:TCON)’s short sellers to cover TCON’s short positions. The SI to Tracon Pharmaceuticals Incorporated’s float is 4.08%. About 31,823 shares traded. TRACON Pharmaceuticals Inc (NASDAQ:TCON) has declined 52.06% since June 27, 2016 and is downtrending. It has underperformed by 68.76% the S&P500.

Sasco Capital Inc decreased Raytheon (NYSE:RTN) stake by 214,525 shares to 1.26 million valued at $178.64M in 2016Q4. It also reduced Republic Services Inc (NYSE:RSG) stake by 743,310 shares and now owns 3.16M shares. Ball Corp (NYSE:BLL) was reduced too.

Among 11 analysts covering Sealed Air Corporation (NYSE:SEE), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Sealed Air Corporation had 20 analyst reports since August 4, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $52 target in Thursday, July 14 report. The rating was maintained by Jefferies on Wednesday, April 19 with “Hold”. RBC Capital Markets initiated the shares of SEE in report on Friday, February 19 with “Outperform” rating. Goldman Sachs downgraded it to “Buy” rating and $50 target in Wednesday, April 5 report. SunTrust initiated the stock with “Buy” rating in Wednesday, July 13 report. As per Tuesday, September 13, the company rating was initiated by JP Morgan. The stock of Sealed Air Corp (NYSE:SEE) has “Buy” rating given on Tuesday, August 23 by UBS. The stock of Sealed Air Corp (NYSE:SEE) earned “Overweight” rating by Barclays Capital on Friday, January 8. As per Tuesday, November 10, the company rating was downgraded by Macquarie Research. The company was downgraded on Tuesday, September 15 by Bank of America.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $38.22 million. The Firm is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. It currently has negative earnings. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. Roth Capital initiated the shares of TCON in report on Wednesday, July 29 with “Buy” rating. Zacks upgraded the stock to “Hold” rating in Friday, September 4 report. As per Wednesday, December 21, the company rating was initiated by Jefferies. The firm earned “Buy” rating on Wednesday, July 29 by TH Capital.


Gebruikersavatar
Pantanirulez
Forum gebruiker
Forum gebruiker
Berichten: 147
Lid geworden op: 17 Aug 2015 15:32
waarderingen: 55
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON) -NasdaqGM 11.99$

Berichtdoor Pantanirulez » 29 Jun 2017 12:34

http://www.wsnews4investors.com/2017/06/29/watch-list-sizzling-volatility-to-focus-on-tracon-pharmaceuticals-inc-tcon-along-weekly-value-of-8-89/


WATCH-LIST – SIZZLING VOLATILITY TO FOCUS ON TRACON PHARMACEUTICALS, INC. (TCON) ALONG WEEKLY VALUE OF 8.89%

June 29, 2017 By Steve Watson 0
TRACON Pharmaceuticals, Inc. (TCON) has Weekly volatility of 8.89% and monthly volatility of 8.49%. The stock price escalated 10.11% to finalize at $2.45 throughout previous buying and selling session. A total of 0.14 million shares exchanged at hands and its average trading volume is standing at 0.07 million shares. Important factors to focus when evaluating a stock’s present and future value are the 52 week price high and low levels. Shares of TRACON Pharmaceuticals, Inc. (TCON) are trading -66.44% downward from the 52-week high mark and 22.50% above from the fifty two-week low mark.

Taking a glance at past performance, we will examine different up or down moving trends about TCON. The stock added 13.95% beyond one week and declined -5.77% during previous one month session. The stock went down -37.18% at some stage in past quarter. Inside the closing six months period the stock’s performance declined -52.43% while overall yearly performance lost -45.43%. The Company’s year to date (YTD) performance is now negative at -50.00%. The company has a Return on Assets (ROA) of -69.90%. Presently, it has a Return on Equity (ROE) of -126.70% and Return on Investment (ROI) of -72.80%. Tracking most recent quarter period, Price to book (P/B) ration is at 1.73 and Price to cash per share ration is at 1.07.

TRACON Pharmaceuticals, Inc. (TCON) stock price away from 20 day simple moving average surged at 3.60% while its distance from 50 day simple moving average declined -16.81% along with -46.35% below away from two hundred simple moving averages. The time frame or length you choose for a moving average, also called the “look back period”, can play a big role in how effective it is. An MA with a short time frame will react much quicker to price changes than an MA with a long look back period. The 20-day may be of analytical benefit to a shorter-term trader since it follows the price more closely, and therefore produces less “lag” than the longer-term moving average. Lag is the time it takes for a moving average to signal a potential reversal. Recall, as a general guideline, when the price is above a moving average the trend is considered up. So when the price drops below that moving average it signals a potential reversal based on that MA. A 20-day moving average will provide many more “reversal” signals than a 100-day moving average.

Relative strength index (RSI-14) for TRACON Pharmaceuticals, Inc. (TCON) is at 46.83. In phrases of Market analysis and buying and selling signals, RSI moving above the horizontal 30 reference standard is regarded as a bullish indicator, at the same time as the RSI transferring under the horizontal 70 reference standard is visible to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely moves underneath 30 notify oversold conditions.

While taking a look at financials, we can look at a number of key indicators about TRACON Pharmaceuticals, Inc. (TCON). Average true range (ATR-14) of the company is at 0.21. Developed by J. Welles Wilder, ATR is an indicator that measures volatility. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. It may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system.


Gebruikersavatar
Jojo
Premiummember
Premiummember
Berichten: 498
Lid geworden op: 19 Dec 2013 15:26
waarderingen: 151
Contact:

Re: TRACON Pharmaceuticals, Inc. (TCON) -NasdaqGM 11.99$

Berichtdoor Jojo » 25 Jul 2017 18:49

Gilead Ageas Genmab ASMI Sphere3D GSK CFEB LBrands Melexis Umicore Euronav Nordex Solvay Grandvision Biocartis AXA Befimmo AHDelh ABInbev TCON ACIU BMW RioTinto